A phase Ib/II study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer (mCRPC) and no mutations in DNA damage repair (DDR) Meeting Abstract

  

Authors:	Autio, K. A.; Kyriakopoulos, C.; Xiao, H.; Emamekhoo, H.; Danila, D. C.; Devitt, M. E.; Riedel, E.; Jan, M.; Scher, H. I.
Abstract Title:	A phase Ib/II study of intermittent talazoparib plus temozolomide in patients with metastatic castration-resistant prostate cancer (mCRPC) and no mutations in DNA damage repair (DDR)
Meeting Title:	2023 ASCO Annual Meeting
Journal Title:	Journal of Clinical Oncology
Volume:	41
Issue:	16 Suppl.
Meeting Dates:	2023 Jun 2-6
Meeting Location:	Chicago, IL
ISSN:	0732-183X
Publisher:	American Society of Clinical Oncology
Date Published:	2023-06-01
Language:	English
DOI:	10.1200/JCO.2023.41.16_suppl.e17036
PROVIDER:	EBSCOhost
PROVIDER:	cinahl
DOI/URL:	https://search.ebscohost.com/login.aspx?direct=true&AuthType=ip,shib&db=cin20&AN=164016561&authtype=sso&custid=s2915669&site=ehost-live&scope=site&custid=s2915669
Notes:	Meeting Abstract: e17036 -- Meeting was also available virtually -- Source: Cinahl

https://synapse.mskcc.org/synapse/works/has_related_data_chk/209606